Loading
Life sciences · Journal article
The Prostate · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain. This study aims to determine whether one ARPI is associated with longer overall survival (OS) than the other, expanding upon prior work through inclusion of a contemporary patient cohort and examination of how comorbidities influence OS. Methods Using data from the nationwide Veterans Affairs (VA) healthcare system, we identified 8859 veterans with mCRPC treated with either abiraterone or enzalutamide between September 2014 and September 2022. Patients with prior docetaxel exposure were excluded, and frailty was defined using the VA Frailty Index (VA‐FI). Analyses were weighted for clinical covariates, including age, race, and BMI, using IPTW. Kaplan–Meier analysis was used to compare OS between treatment groups. Results Among frail patients with mCRPC, enzalutamide treatment was associated with longer OS compared to abiraterone (22.8 vs. 20.9 months, p = 0.001). Similarly, enzalutamide was associated with longer OS than abiraterone among patients with cardiovascular disease or diabetes (26.3 vs. 23.9 months, p = 0.023) and among patients without cardiovascular disease or diabetes (30.0 vs. 28.0 months, p = 0.019). Conclusions Enzalutamide was associated with improved OS compared to abiraterone in frail patients with mCRPC, regardless of comorbid cardiovascular disease or diabetes. These findings highlight the importance of considering specialized patient populations, including frailty and comorbidity profiles, in ARPI selection and clinical care. Trial Registration: NA